Pfizer Inc. (NYSE: PFE) is scheduled to report its fourth-quarter financial results before the markets open on Tuesday. The consensus estimates from Thomson Reuters are $0.52 in earnings per share (EPS) on $13.57 billion in revenue. In the same period of the previous year, Pfizer posted EPS of $0.54 and $13.11 billion in revenue.
Be advised that the earnings and revenue estimates may change ahead of the formal reports.
This stock could be offering investors a great value at current trading levels. Pfizer rocked Wall Street last year by announcing a gigantic $15.2 billion purchase of Hospira, a top provider of sterile injectable drugs — including those used for acute care and cancer treatment — infusion technologies and biosimilars, which are subsequent versions of drugs whose patents have expired.
With a strong pipeline and the fact that Pfizer is the world’s largest drug manufacturer by sales volume, many analysts feel the company can generate higher long-term revenues through the accelerated growth of its new drugs over the next five years, with Ibrance leading the way. Some on Wall Street also predict that the company will make an accretive acquisition between now and the end of 2016.
[recirclink id=312146]
Sales of Ibrance totaled more than $250 million in the firm’s most recent quarterly earnings report. The pill, which essentially doubled the survival rate for certain advanced breast cancer patients, is already being widely prescribed.
In the most recent settlement date, Pfizer saw its short interest remain relatively flat at 123.23 million shares, relative to the previous 123.45 million. The highest short interest reading over the past year was 207.4 million.
So far in 2016, Pfizer is more or less in line with the broad markets, with the stock is down about 5.6% year to date. Over the past 52 weeks, the stock is down only 1%.
Shares of Pfizer were trading at $29.90 on Monday, with a consensus analyst price target of $40.19 and a 52-week trading range of $28.47 to $36.46.
Top Gaining Stocks
Top Losing Stocks